OncoSec Medical Inc Short ratio
Cos'è Short ratio di OncoSec Medical Inc?
Short ratio di OncoSec Medical Inc è 0.32
Qual è la definizione di Short ratio?
Short ratio è il numero di azioni vendute breve diviso per il volume medio giornaliero.
Short ratio is calculated by dividing the number of shares sold short by the average daily trading volume, generally over the last 30 trading days. The ratio represents the number of days it takes short sellers on average to repurchase all the borrowed shares. The ratio is used by both fundamental and technical traders to identify trends.
The percentage represents the number of days it takes short sellers on average to repurchase all the borrowed shares. Short selling is the practice of selling securities or other financial instruments that are not currently owned, and subsequently repurchasing them. In the event of an interim price decline, the short seller profits, since the cost of (re)purchase is less than the proceeds received upon the initial (short) sale. Conversely, the short position closes out at a loss if the price of a shorted instrument rises prior to repurchase. A high short ratio can be an indicator that there will be some buying pressure on the security that would increase its price.
Short ratio di aziende nel Health Care settore su NASDAQ rispetto a OncoSec Medical Inc
Cosa fa OncoSec Medical Inc?
oncosec is a san diego-based biotechnology company pioneering new technologies to stimulate the body’s immune system to target and attack cancer. through our proprietary technology, we hope to deliver safer and more effective cancer treatments that can provide long-term benefits for patients. our technology, immunopulse™, is designed to enhance the local delivery and uptake of dna-based immune-targeting agents, such as il-12. clinical trials of immunopulse™ il-12 demonstrated a favorable safety profile and evidence of anti-tumor activity in the treatment of various skin cancers as well as the potential to initiate a systemic immune response. our lead program, immunopulse™ il-12, is currently in phase ii development for several indications, including metastatic melanoma, squamous cell carcinoma of the head and neck, and triple-negative breast cancer. to date, study results have laid the groundwork for the expansion into new dna-encoded therapeutic candidates and tumor indications. we ar
Aziende con short ratio simili a OncoSec Medical Inc
- Yangtze River Port and Logistics Ltd ha Short ratio di 0.31
- Jupai Ltd ha Short ratio di 0.31
- TORC Oil & Gas ha Short ratio di 0.31
- Zhangmen Education ha Short ratio di 0.31
- Nicola Mining ha Short ratio di 0.31
- Invesco Municipal Opportunity Trust ha Short ratio di 0.31
- OncoSec Medical Inc ha Short ratio di 0.32
- Last Mile ha Short ratio di 0.33
- Bitcoin Well Inc ha Short ratio di 0.33
- Euro Manganese ha Short ratio di 0.33
- Quebec Precious Metals ha Short ratio di 0.33
- Collective Growth ha Short ratio di 0.33
- FRNT ha Short ratio di 0.33